18 November 2015 - The European Commission has approved the expanded use of ivacaftor in children with cystic fibrosis ages 2 to 5 who have one of 9 gating mutations; approximately 125 children ages 2 to 5 have one of the approved gating mutations in Europe.

For more details, go to: http://investors.vrtx.com/releases.cfm?hdr02=press